European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C

3 June 2016
250 Views

Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.

The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.

You may be interested

Folegandros: Images of an undiscovered gem
GREECE
shares307 views
GREECE
shares307 views

Folegandros: Images of an undiscovered gem

Panos - Jul 19, 2018

Shining under the Aegean sun, Folégandros was named after the son of King Minos. This off-the-beaten-path destination captivates the visitors…

Majestic natural pools you have to visit once!
TRAVEL
shares200 views
TRAVEL
shares200 views

Majestic natural pools you have to visit once!

Panos - Jul 19, 2018

Natural pools are always the best way to cool down in the heat. Surrounded by some of the most beautiful…

European Commission vs. Tech giants
WORLD
shares23 views
WORLD
shares23 views

European Commission vs. Tech giants

Panos - Jul 19, 2018

The European Commission’s record-breaking €4.34 billion ($5.1b) fine against Google is by no means the first time that the EU’s…

Leave a Comment

Your email address will not be published.